GLP-1 Receptor Agonist Therapy in Children and Adolescents with Obesity: A Network Meta-Analysis of Differential Cardiometabolic Efficacy and Safety Profiles
Semaglutide produces the largest weight reductions in teenagers with obesity, though findings are preliminary and different drugs excel at different health outcomes.
A Bayesian network meta-analysis of 17 RCTs (1230 adolescents) found semaglutide 2.4 mg SC associated with the largest reductions in body weight, BMI, and waist circumference in adolescents with obesity, while dulaglutide 1.5 mg showed the largest HbA1c improvement. Most active-treatment comparisons were indirect through sparse networks, so agent rankings are hypothesis-generating and should not be interpreted as definitive clinical superiority.
What the study was
- Study design
- Bayesian network meta-analysis (17 RCTs, n=1230 adolescents with obesity)
- Population
- 1230 children and adolescents with obesity enrolled in 17 RCTs
- Sample size
- 1230
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Pharmacol Res
Why it surfaced
First network meta-analysis comparing GLP-1RAs in adolescent obesity; 17 RCTs, 1230 participants; semaglutide vs dulaglutide differentiation in a high-priority expanding patient population.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.